© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Jason Starr, DO, discusses the importance of molecular residual disease within the cancer treatment landscape.
December 22nd 2021
Jason Starr, DO, provides an overview of molecular residual disease (MRD) in the hematological and oncological treatment landscapes.
Jason Starr, DO, explains circulating tumor DNA’s (ctDNA) role in oncology and its role in MRD.
January 27th 2022
Jason Starr, DO, discusses MRD assessments, including: when they are done, where the testing takes place, and how often they are recommended.
Kashyap Patel, MD, and Jason Starr, DO, explain the various potential uses for MRD results and how they guide treatment decisions.
February 3rd 2022
Dr Patel describes the importance of MRD in value-based care models.
Our experts tell us how we can support the availability of MRD for more patients.
February 9th 2022
Jason Starr, DO, discusses the INSPIRE and IMvigor011 studies that focused on the use of ctDNA in MRD.
Kashyap Patel, MD, and Jason Starr, DO, explain the potential changes providers might see in the future for MRD.